Beyond Diabetes and Obesity: Researchers are studying numerous additional indications that could expand the use of these medications beyond diabetes and obesity
Research suggests it activates AMPK pathways, the same pathway targeted by exercise and caloric restriction, positioning it as a key subject in longevity and metabolic disease research
Patients will be able to access ongoing consultations via video chat, as well as a nutrition, fitness and mindfulness content library
Commonly prescribed GLP-1 receptor agonists in the UK include: Semaglutide (Ozempic, Wegovy, Rybelsus [oral formulation]) Dulaglutide (Trulicity) Liraglutide (Victoza, Saxenda) Exenatide (Byetta [twice-daily], Bydureon [weekly]) Tirzepatide (Mounjaro) - a dual GIP/GLP-1 receptor agonist with similar considerations [6] [7] These medications are typically administered via subcutaneous injection (daily, twice-daily or weekly depending on the specific formulation), with semaglutide also available as an oral tablet
Obesity is a well-established risk factor for reduced fertility, including lower clinical pregnancy and live birth rates and increased miscarriage risk [8]
